<DOC>
	<DOCNO>NCT00258310</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving capecitabine surgery , radiation therapy , and/or chemotherapy may kill remain tumor cell . PURPOSE : This phase II trial study well capecitabine work treat patient undergone previous surgery , radiation therapy , and/or chemotherapy head neck cancer .</brief_summary>
	<brief_title>Ph II Study Examining Long Term/Low Dose Xeloda Head Neck Squamous Cell Carcinoma After Surgery , Radiation &amp; /or Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility adjuvant low-dose capecitabine patient squamous cell carcinoma head neck undergone prior curative surgery , radiotherapy , and/or chemotherapy . Secondary - Determine time recurrence , local-regional control , survival rate patient treat drug . - Determine incidence second primary tumor patient treated drug . OUTLINE : This open-label study . Patients receive oral capecitabine daily 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 1 year . PROJECTED ACCRUAL : A total 41 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck , include 1 follow primary tumor site : Oral cavity Oropharynx Nasopharynx Hypopharynx Larynx Unknown primary Any disease stage allow No evidence active disease Must undergone curative surgical resection , radiotherapy , and/or chemotherapy least 1 month , 4 year ago PATIENT CHARACTERISTICS : Performance status Karnofsky 70100 % Life expectancy More 3 month Hematopoietic White blood count ( WBC ) ≥ 3,000/mm^3 Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Hepatitis B and/or C negative Renal Creatinine clearance &gt; 50 mL/min Cardiovascular No myocardial infarction within past 12 month No uncontrolled congestive heart failure No unstable uncontrolled angina Gastrointestinal No lack physical integrity upper gastrointestinal tract Must able swallow tablet No malabsorption syndrome Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer patient currently complete remission No history uncontrolled seizure , central nervous system ( CNS ) disorder , psychiatric disability would preclude study compliance give informed consent No ongoing postoperative fistula No prior unanticipated severe reaction fluoropyrimidine therapy know sensitivity fluorouracil No serious uncontrolled medical surgical condition would preclude study participation PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics Prior oral fluoropyrimidine therapy allow provide give adjuvant setting complete ≥ 12 month ago Radiotherapy See Disease Characteristics Surgery See Disease Characteristics More 4 week since prior major surgery recover No prior organ allografts Other More 4 week since prior participation investigational drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>